✦ LIBER ✦

An estimate of the cost-effectiveness of combined modality therapy for stage IIIb NSCLC in Canada

Book ID: 123316513
Publisher: Elsevier Science
Year: 1994
Tongue: English
Weight: 166 KB
Volume: 11
Category: Article
ISSN: 0169-5002
DOI: 10.1016/0169-5002(94)94115-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The role of combined modality therapy in

The role of combined modality therapy in symptomatic Hodgkin's disease, stage IB–IIIB

✍ Peter Mauch; MaryEllen Ryback; Alan Lewin; David Rosenthal; Samuel Hellman 📂 Article 📅 1980 🏛 Elsevier Science 🌐 English ⚖ 196 KB

Combined modality therapy for stage IIIA

Combined modality therapy for stage IIIA (clinical N2) Non-Small Cell Carcinoma of the Lung (NSCLC)

📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Estimating the Population Impact of Intr

Estimating the Population Impact of Introducing Stereotactic Ablative Radiation Therapy for Stage I NSCLC in Canada

✍ Louie, A.V.; Rodrigues, G.; Palma, D.A.; Senan, S. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 48 KB

1057 The health economics of lung cancer

1057 The health economics of lung cancer and an estimate of the cost effectiveness of single agent gemcitabine in stage IV NSCLC

✍ Evans, W.K. 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Development of a Multi parametric Cost-E

Development of a Multi parametric Cost-Effectiveness Model for Comparison of Therapeutic Modalities in Definitive Radiation Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)

✍ Richard, P.; Phillips, M.; Zeng, J.; Halasz, L.; Fang, L.; Apisarnthanarax, S.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Results of combined-modality therapy for

Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly

✍ Steven E. Schild; Philip J. Stella; Burke J. Brooks; Sumithra Mandrekar; James A 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

## Abstract ## BACKGROUND A Phase III trial was conducted by the North Central Cancer Treatment Group to determine whether chemotherapy (etoposide and cisplatin) plus either twice‐daily radiotherapy (BIDRT) or once‐daily radiotherapy (QDRT) resulted in a better outcome for patients with limited‐st